Antisoma's MOA support

Antisoma plc has been developing its AS1411 for acute myelogenous leukemia and renal cancer based on its ability to induce apoptosis in cancer cells while sparing healthy cells. Exactly how the aptamer does this has not been well understood.

Last week, Professor of Biochemistry and Molecular Biology Daniel Fernandes and colleagues at the Medical University of South Carolina published studies in breast cancer cell lines in Cancer Researchthat support a previously suspected role for AS1411 in destabilizing Bcl-2 mRNA...